NCT00343408 is a Phase 1 clinical trial of cediranib maleate in Colorectal Cancer, sponsored by NCIC Clinical Trials Group.

Who is sponsoring NCT00343408?

NCT00343408 is sponsored by NCIC Clinical Trials Group.

What drugs are being tested in NCT00343408?

Interventions in NCT00343408: cediranib maleate, cisplatin, fluorouracil, gemcitabine hydrochloride, leucovorin calcium, oxaliplatin.

What condition does NCT00343408 study?

NCT00343408 studies Colorectal Cancer, Lung Cancer.

Is NCT00343408 still recruiting?

NCT00343408 is currently completed. Last updated 4 August 2023.

Last reviewed 2023-08-04 · How we verify

NCT00343408

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer

Completed Phase 1 Last updated 4 August 2023

What this trial tests

Phase 1 trial testing cediranib maleate in Colorectal Cancer in 31 participants. Completed in 22 September 2008.

Timeline

29 November 2005

Primary endpoint
18 September 2007

22 September 2008

Quick facts

Lead sponsor	NCIC Clinical Trials Group
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	31
Start date	29 November 2005
Primary completion	18 September 2007
Estimated completion	22 September 2008
Sites	3 locations across Canada

Drugs / interventions tested

cediranib maleate
cisplatin (cisplatin) — full drug profile →
fluorouracil — full drug profile →
gemcitabine hydrochloride — full drug profile →
leucovorin calcium
oxaliplatin (Oxaliplatin) — full drug profile →

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →
Lung Cancer — all drugs for Lung Cancer →

Sponsor

NCIC Clinical Trials Group

Who can join

Adults 18 to 120, any sex, with Colorectal Cancer or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving AZD2171 together with standard combination chemotherapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of AZD2171 when given together with standard combination chemotherapy in treating patients with advanced non-small cell lung cancer (NSCLC) or colorectal cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of cediranib maleate

Trials testing the same drug.

NCT00795340 — Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer · Phase 3 · completed
NCT00245154 — Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer · Phase 2, PHASE3 · completed
NCT00107250 — AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (N · Phase 1 · completed

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other NCIC Clinical Trials Group trials

Trials by the same sponsor.

NCT01916187 — Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma · Phase 1 · withdrawn
NCT01830621 — BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma · Phase 3 · completed
NCT01652144 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma · Phase 2 · completed
NCT01627054 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia · Phase 2 · completed
NCT01486368 — A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00343408 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NCIC Clinical Trials Group
Last refreshed: 4 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00343408.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing